News
RIGL
31.39
+4.74%
1.42
Weekly Report: what happened at RIGL last week (0406-0410)?
Weekly Report · 1d ago
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Seeking Alpha · 6d ago
Rigel grants 8,925 inducement RSUs to six new employees under NASDAQ rule 5635(c)(4)
Reuters · 04/07 12:06
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · 04/07 12:05
Weekly Report: what happened at RIGL last week (0330-0403)?
Weekly Report · 04/06 10:29
Rigel Pharmaceuticals announces annual shareholder meeting
Reuters · 04/03 20:03
Rigel Pharmaceuticals Balances Breakout Growth With Caution
TipRanks · 04/02 00:12
Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC
Reuters · 03/31 21:44
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
Benzinga · 03/31 14:51
Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Rigel (RIGL)
TipRanks · 03/31 14:30
Rigel Pharmaceuticals Publishes Final Data From Phase 1/2 ARROW Trial Of Pralsetinib To Treat Metastatic Rearranged During Transfection Fusion-Positive Non-Small Cell Lung Cancer
Benzinga · 03/31 12:21
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial
TipRanks · 03/31 12:14
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
PR Newswire · 03/31 12:05
Weekly Report: what happened at RIGL last week (0323-0327)?
Weekly Report · 03/30 10:29
Top 10 undervalued small-cap stocks with high growth grades
Seeking Alpha · 03/26 16:12
Weekly Report: what happened at RIGL last week (0316-0320)?
Weekly Report · 03/23 10:25
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors
TipRanks · 03/20 16:31
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
The Motley Fool · 03/16 22:56
Weekly Report: what happened at RIGL last week (0309-0313)?
Weekly Report · 03/16 10:24
Rigel Pharmaceuticals publishes corporate presentation on commercial product sales growth and development pipeline expansion
Reuters · 03/10 20:15
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.